Status:
TERMINATED
The Effect of Caphosol® on the Development of Esophagitis in (N)SCLC Patients Treated With Concurrent Chemo/Radiotherapy
Lead Sponsor:
Amphia Hospital
Collaborating Sponsors:
Erasmus Medical Center
Conditions:
Small Cell Lung Cancer
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Rationale: In the Netherlands 1770 people are being diagnosed with SCLC (Small Cell Lung Cancer) and 8764 patients are being diagnosed with NSCLC (Non Small Cell Lung Cancer) in 2011. This is approxim...
Eligibility Criteria
Inclusion
- 18 years or older
- Patients with histologically proven (N)SCLC (all histological subtypes), treated with concurrent chemo- and radiotherapy.
- Ability to understand the protocol and willing to provide written informed consent
Exclusion
- Concurrent participation in a clinical trial in which the subject is taking or receiving any investigational agent that may affect the frequency, severity or duration of mucositis.
- Pre-existent esophagitis.
- Receiving investigational treatment for the prevention or treatment of mucositis.
- Prior irradiation to the lung or head and neck region.
Key Trial Info
Start Date :
February 25 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2016
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT01809756
Start Date
February 25 2014
End Date
June 1 2016
Last Update
April 7 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Amphia Hospital
Breda, North Brabant, Netherlands, 4818 CK
2
Erasmus Medical Centre
Rotterdam, Netherlands, 3015AA